Introduction
Neuroblastoma (NB) and ganglioneuroblastoma (GNB) are heterogeneous childhood malignant tumors that derive from the neuroectodermal stem cells and, along with ganglioneuroma (GN), are collectively designed as neuroblastic tumors (NTs) (Shimada et al., 1999) . NB and GNB can be subdivided into three biological and clinical subtypes that are predictive of clinical behavior, whereas GN is a well-differentiated benign tumor that presents an excellent prognosis (Brodeur, 2003) . Through the combined clinical and biological classification of the patients, the therapeutic protocols can be optimized to reduce adverse effects and improve the quality of the life of the children affected by malignant NTs (Shimada et al., 1999; Westermann and Schwab, 2002; Brodeur, 2003) .
In the recent years, the identification of many genetic abnormalities and of several impaired biological pathways in NB cells has lead to the proposal of several models that could explain the development of this tumor. Nevertheless, NTs remain a biological enigma and it is not clear if they represent the same or different diseases.
The amplification of the MYCN oncogene is so far the most widely recognized molecular prognostic marker in malignant NTs. This event, however, underestimates the proportion of patients at risk of progression, since MYCN amplification is detected in only approximately 30% of the patients, and rapidly progressive disease often occurs also in MYCN-single copy patients. Therefore, the identification of additional, predictive, biological markers may have important implications in the management of this disease.
Methylation of CpG-rich promoter regions of genes involved in many biochemical pathways is common in cancer cells and is considered an essential step in cancer development. The aberrant hypermethylation can induce point mutations and, by altering the chromatin conformation, can also silence tumor suppressor genes modifying the interaction with the transcription machinery Esteller, 2003; Laird, 2003) . On the other hand, hypomethylation of specific sequences may reactivate the expression of potentially oncogenic genes (Esteller and Herman, 2002) . Indeed, the expression of the oncogenic and antioncogenic isoforms of the p73 gene is regulated also through a complex mechanism of methylation/demethylation that differently affects the two promoters of this gene (Corn et al., 1999; Kawano et al., 1999; Banelli et al., 2000; Casciano et al., 2002a, b) . Importantly, methylation can be regarded also as an easily detectable cancer marker or as a marker for tumor behavior, and the aberrant methylation of multiple genes may be a unique characteristic of distinct tumors or of tumor subtypes with different biological or clinical features. In this respect, the definition of methylation profiles may represent a highly promising method to identify groups of patients at risk of tumor progression and those likely to benefit from individually tailored therapeutic regimens (Esteller, 2003; Laird, 2003) . Indeed, in colorectal cancer, the 'CpG island methylator phenotype', a condition where a specific set of genes is a frequent target of aberrant methylation (Toyota et al., 1999) , is an independent predictor of good survival from 5-Fluorouracil (5-FU)-based adjuvant chemotherapy (Van Rijnsoever et al., 2003) .
In the present study, we investigated the possibility that specific methylation profiles are associated with unique biological and clinical parameters of NTs and, in particular, if they can identify different risk groups among the patients. To test this hypothesis, we have determined the methylation status of a panel of genes belonging to different biological pathways that are frequent target of aberrant methylation in adult and pediatric tumors and we have observed significant differences of the methylation status of different genes in biologically and clinically distinct groups of NTs.
Results and discussion

Genes and patients selection
We have determined the methylation profile of 11 genes that either are frequently methylated in cancer (14.3.3s, RASSF1A, CDKN2A, CDH1), or that are involved in important apoptotic, differentiation or drug response pathways (CASP8, DCR2, RARB2, DR4, MGMT), or that are considered important for NB development (TAp73, DNp73). This analysis was conducted on 31 NB at various stages and on 13 GN. The relevant clinical and biological characteristics of the NB patients included in the study are reported in Table 1 . The aim of our work was to test the hypothesis that differences in the methylation pattern of selected genes could contribute to distinguish the major clinical subgroups of NTs. To evaluate the association between methylation and MYCN amplification, we analysed an equivalent number of MYCN-single copy and MYCN-amplified NB. As expected, the risk of disease progression was higher in the MYCN-amplified patients (RR ¼ 2.89; P ¼ 0.05).
In our study, the MYCN-single copy GN were always considered as a distinct clinicobiological entity and, because of the benign nature of this tumor, they were not included in the survival analyses.
The methylation status was generally determined by methylation-specific PCR (MSP) (Herman et al., 1996) ; however, for DNA regions that are not canonical CpG island, we utilized the bisulfite resctriction enzyme analysis (BRE) (Sadri and Hornsby, 1996) or the direct sequencing after bisulfite conversion (Frommer et al., 1992) . Italic value represent the percentage of the patients presenting the covariate.
Methylation analysis of caspase 8 promoter and intragenic sequence
Caspase 8 has an essential and nonredundant role in programmed cell death. We have identified a CASP8 promoter and shown that, in cell lines, the silencing of this gene does not depend directly from the methylation of CpG doublets. Rather, it likely reflects the epigenetic inactivation of genes that transactivate CASP8 (Banelli et al., 2002) .
The low CpG density and the absence of informative restriction enzyme sites in the CASP8 promoter did not allow utilizing MSP or BRE for the methylation analysis of this region in primary tumors. Therefore, the methylation status of seven CpG doublets within the CASP8 promoter was precisely determined by sequencing the À278/ þ 79 DNA segment (at exon 1) after bisulfite treatment of the tumor DNA. The results of this experiments showed that this region is variably methylated, independently from the MYCN amplification status, not only in NB but also in GN, and that methylation density is independent from The methylation level of the intragenic sequence between exons 2 and 3, initially considered as a CASP8 'regulatory' region (Teitz et al., 2000) , although located (Figure 1 , panels b and c). Another CpG doublet (HinfI and 2) was marginally hypermethylated in MYCN-amplified tumors whereas two other CpGs, identified by the HinfI sites 1 and 3, did not show appreciably different levels of methylation in the NB samples included in our study. Differently from NB, the same region appears completely unmethylated in benign GN.
In conclusion, these experiments confirm and extend our previous finding and identify major differences in the methylation status of an intragenic sequence of the CASP8 gene between benign and malignant neuroblastic tumors and between MYCN-amplified and -single copy NB.
Absence of methylation in genes that are common targets of methylation in adult tumors
The different level of methylation in the intragenic sequence of CASP8 between MYCN-amplified and -single copy tumors suggested the existence of methylation errors in malignant NTs and that methylation differences could distinguish NB subtypes with distinct biological characteristics. To verify this hypothesis, we have determined by MSP and/or BRE the methylation pattern of nine genes that contain true CpG islands in their promoter region and that are frequent targets of hypermethylation in a variety of adult and pediatric tumors. The RARB2, a gene whose promoter is enriched in CpGs, was also included although it does not contain a canonical island.
The results of these experiments, summarized in Figures 2 and 3, indicate that a series of target genes (DR4, CDKN2A, RARB2, MGMT, TAP73 and CDH1) are never methylated in either NB or GN. The absence of methylation of the RARB2 gene in advanced stage NTs was an unexpected finding since this gene is inactivated by CpG methylation in adult tumors (Widschwendter et al., 1997) and, in NB, its lack of expression identifies a subgroup of highly aggressive tumors (Cheung et al., 1998) . The absence of RARB2 methylation observed in our study agrees with two previous reports where the same region was analysed under different experimental conditions (Harada et al., 2002 , Yang et al., 2004 . Surprisingly, in a recent survey for methylated genes, RARB2 methylation was detected in a small number of NTs, mainly GN, and consequently, was considered an indicator of favorable outcome (Alaminos et al., 2004) . However, it should be pointed out that the detection of methylated samples in our cohort would have been unlikely because of the very low prevalence of RARB2 methylation in neuroblastic tumors (6.8%, Alaminos et al., 2004) . The DR4 gene, a TRAIL signaling mediator, is unmethylated in primary malignant and benign NTs. Our results agree with a recent survey of methylation conducted, on the identical region, in nine neuroblastoma cell lines and 28 primary neuroblastoma reporting that DR4 is methylated in the NB cell lines but not in primary tumors (van Noesel et al., 2002) . This latter observation may suggest that DR4 methylation was acquired in cell culture. A dramatically different result was recently reported in an independent study indicating that DR4 is the most frequently methylated gene among those included in that survey (49.7% of 145 NTs) (Alaminos et al., 2004) . It is possible that differences in the reaction conditions (extent of bisulfite conversion and differences in the primers sequence or PCR conditions) may be responsible for these conflicting results. It is expected that in the near future the standardization of the techniques will help to clarify these controversial and somehow confusing aspects of the methylation analysis of NTs.
Methylation profile of 14.3.3s, DNp73, RASSF1A and DCR2
Four genes (14.3.3s, DNp73, RASSF1A and DCR2) are variably methylated in NTs. The methylation profile detected in GN was identical in all samples and significantly different from that of malignant NB (Figure3 and Table 2 ).
The 14.3.3s gene is a G2 checkpoint regulator that is aberrantly hypermethylated in several tumors. In GN, this gene always displays partial methylation, whereas it is fully methylated in a significant portion of MYCNamplified NB (Figure 4) . Indeed, 78% of MYCNamplified tumors, but only 23% of the MYCN-single copy NB, show complete methylation of this gene (Po0.01). The biological significance of the partial methylation observed for the 14.3.3s gene in GN is unclear; this result might reflect either the composite structure of this tumor or a complex pattern of methylation. In this respect, partial methylation of this gene was observed also in homogeneous tumor cell populations prepared by microdissection of primary breast cancer (Ferguson et al., 2000) .
The p73 gene, a homologue of the p53 tumor suppressor gene, transactivates several p53 target genes, induces apoptosis, and inhibits cell proliferation. N-terminal-deleted isoforms of this gene have opposite functions and act as an oncogene in vitro (reviewed by Melino et al., 2002) . Indeed, we have observed that the aberrant expression or the overexpression of the truncated DNp73 variant is a negative prognostic factor in NB patients independently from MYCN amplification, age and stage (Casciano et al., 2002b) . The p73 gene has at least two distinct promoters: promoter 1 (p73-P1), upstream of exon 1, regulates the expression of the transactivating isoform (TAp73) and of some truncated variants (del Ex2p73, DN 0 -p73), while promoter 2 (p73-P2), within intron 2 and upstream of an alternative exon 3 (exon 3 0 ), regulates the expression of the DNp73 variant (Grob et al., 2001; Casciano et al., 2002a; Melino et al., 2002) . Canonical CpG islands characterize both promoters and p73-P1 is hypermethylated and silenced in hematopoietic malignancies but not in NB. (Corn et al., 1999; Kawano et al., 1999; Banelli et al., 2000) . The DN oncogenic isoform of p73 is minimally expressed or silenced in many normal and tumor cell types and the p73-P2 promoter generally is fully methylated in most of these cells (Casciano et al. (2002a) and our unpublished observations). In a preliminary set of experiments, we have observed that in NB cell lines and in some primary NB samples, the strong expression of DNp73 is accompanied by the partial demethylation of p73-P2 (Casciano et al., 2002a) . After extending the methylation analysis of the p73-P2 promoter to a larger group of NB and GN samples, we have observed that, in agreement with the expression pattern of DNp73, also the demethylation of p73-P2 is independent from MYCN amplification (Fisher exact test, P ¼ 0.44). Furthermore, in agreement with the benign nature of ganglioneuroma, the promoter of this antiapoptotic and oncogenic p73 variant was fully methylated in all GN samples included in this study (Figures 3 and 4) . RASSF1A is a mitosis-specific inhibitor of the anafase-promoting complex and is inactivated by CpG methylation in many tumors including neuroblastoma (Harada et al., 2002; Yang et al., 2004) . As shown in Figures 3 and 4 , the RASSF1A gene is never methylated in GN but is either fully or partially methylated in 83% of NB. Interestingly, we observed that complete methylation was significantly prevalent in the MYCNamplified samples compared to MYCN-single copy tumors (64 and 18%, respectively, Po0.05). Patients with partial or complete methylation at the RASSF1A promoter had a substantially increased relative risk of unfavorable outcome as compared to patients not presenting methylation, although this difference did not reach statistical significance ( Figure 5, panel a) .
The tumor necrosis factor-related related apoptosis inducing ligand decoy receptor DCR2 presents a drastically distinct profile of methylation between benign and malignant neuroblastic tumors. Indeed, DCR2 is never methylated in GN and variably methylated in NB (Po0.01); however, differently from 14.3.3s and RASSF1A, DCR2 methylation is independent from MYCN status .
The DCR2 gene is silenced by aberrant hypermethylation in a variety of tumors (van Noesel et al., 2002) . However, the biological significance of DCR2 silencing in cancer cells is unclear; indeed, the inactivation of this receptor should have antitumor effects by rendering the cells more sensitive to TRAIL-induced apoptosis.
However, the downregulation of DcR2 could also be considered as part of an inefficient defense mechanism activated to inhibit the tumor cell growth. A similar inefficient mechanism might be responsible for the recently described overexpression of the antioncogenic p16 protein in invasive breast carcinoma as compared to benign fibroadenoma or normal breast tissue (Di Vinci et al., 2005) .
The possibility that DCR2 methylation is an indicator of underlying profound alterations at different levels of the cell physiology, which eventually affects the patients outcome, is strongly suggested by the significantly lower overall survival observed in NB patients presenting partial or complete DCR2 promoter methylation as compared to those that are unmethylated ( Figure 5,  panel b) . Furthermore, we observed that when RASS-F1A and DCR2 methylation were considered together, the predictive effect on survival increased with respect to DCR2 alone (RR: 3.15 vs 4.56) ( Figure 5, panel c) .
In the group of patients included in our study, the RASSF1A and DCR2 methylation seems to be a better predictor of disease progression than MYCN amplification (RR: 4.56 vs 2.89); however, a larger cohort of patients needs to be examined before the full potential of methylation analysis in predicting outcome can be established. Furthermore, the overall survival of the 17 patients bearing MYCN-single copy tumors showed the tendency toward a more rapid disease progression in the patients presenting RASSF1A and/or DCR2 methyla- Figure 3 Representative MSP analysis for 14.3.3s, DNp73, RASSF1A and DCR2 on GN and NB. M: reaction with primers specific for the methylated target: UM: reaction with primers specific for the unmethylated target Table 2 Statistical significance between CpG islands methylation and clinical and biological parameters in NTs Finally, the individual and combined effect of RASSF1A and DcR2 methylation on survival was estimated in a multivariate model, which included tumor stage, MYCN amplification, age at diagnosis and chromosome 1p deletion. The point estimates of RRs were not modified, although only the combination of the two genes remained statistically significant (RR ¼ 3.79; 95% CI ¼ 1.01-14.22, Po0.05).
Conclusions
We have determined the methylation profile of 11 genes in NTs of different biological and clinical characteristics, and we have identified two groups of genes that are differently prone to methylation. The first group includes genes that are frequent target of methylation in adult tumors and that, although possibly inactivated in NTs, do not present methylation in their promoter regions (TAp73, DR4, MGMT, RARB2, CDKN2A, CDH1). A second group of genes (CASP8, 14.3.3s, DNp73, RASSF1A and DCR2) show a characteristic and distinct pattern of promoter methylation, differentiating benign and malignant NTs. Furthermore, the methylation status of 14.3.3s and of RASSF1A in MYCNamplified and -single copy tumors was significantly different and provides an additional parameter to distinguish these two clinically distinct subtypes of NTs. In the group of patients included in our study, methylation of the DCR2 gene was associated with reduced overall survival independently from MYCN amplification, suggesting that DCR2 aberrant methylation may be a potential novel predictor of unfavorable outcome. Further studies on a larger cohort of patients are required to confirm this hypothesis.
The simultaneous hypermethylation of multiple genes is defined as CpG Islands methylator phenotype (CIMP) and was originally described in a subset of sporadic colorectal cancer with microsatellites instability (Toyota et al., 1999) . Interestingly, the CIMP þ status is an independent positive predictor of survival in patients treated with 5-FU (Van Rijnsoever et al., 2003) . In the present report, we have identified a similar phenotype that is particularly evident in MYCN-amplified NTs. The correlation between MYCN amplification and this phenotype suggests the existence of alterations of the methylation machinery and indicates a specific role of epigenetic alterations in more aggressive subtypes of NB. The findings from this and previous studies clearly indicate that genes regulating de novo methylation or its maintenance may be considered as possible novel 
Materials and methods
Patients, DNA and RNA samples A total of 17 MYCN-single copy, 14 MYCN-amplified malignant NB and 13 GN were selected from the Italian Neuroblastoma Tissue Bank (Tonini, 1993) . The tumor cell content of NB samples included in the study was, at least, 80% and the clinical and biological characteristics of the patients is reported in Table 1 . Nucleic acids were extracted as previously described (Romani et al., 1999) and the DNA was processed for methylation analysis.
Methylation analysis
DNA methylation was determined by MSP (Herman et al., 1996) (14.3.3s, RASSF1A, CDKN2A, CDH1 DCR2, DR4, MGMT, TAp73, DNp73), by the BRE analysis (Sadri and Hornsby, 1996) (CASP8 and RARB2) or by direct sequencing of DNA fragment cloned after bisulfite modification (CASP8). The sequence of the primers and the PCR conditions utilized for these assays are reported in Table 3 . All primers, with the exception of those for the CASP8 intragenic region, amplify regions corresponding to bona fide promoters. The techniques utilized for the methylation analysis rely upon the bisulfite treatment of genomic DNA for the conversion of unmethylated C into U leaving the methylated C unmodified. For MSP, the bisulfite-treated DNA was amplified with two sets of primers, one specific for methylated template and the other specific for the unmethylated one. Each target sequence of the primers contained at least two CpG doublets and a minimum of five CpGs were considered for each gene promoter. The presence of an amplification band with one of the two sets of primers, or with both sets, indicate complete methylation (or complete unmethylation) or partial methylation, respectively. Each MSP determination was repeated al least three times utilizing a minimum of two distinct preparations of chemically modified DNA. For BRE analysis, the modified DNA was first amplified by PCR with a set of primers that do not contain CpG residues to avoid the differential amplification of the methylated vs the unmethylated template. The digestion of these PCR products with enzymes that contain a CpG doublet in the recognition sequence generates a unique pattern of fragments whose relative intensity reflects the percentage of methylation of the CpG doublet within the restriction enzyme site. The semiquantitative evaluation of the level of methylation was performed by densitometric analysis of the acquired gel images with the Alpha DigiDoct1000 software. The band intensity was transformed in percentage of methylation. BRE was the primary technique for methylation analysis of CASP8 (intragenic region) and RARB2, because these sequences are not canonical islands and we have observed that BRE gives more accurate results, as compared to MSP, on low-CpG content targets. The restriction enzymes utilized for this analysis were: HinfI and TaqI for RARB2 and HinfI, TaqI and RsaI for CASP8; these digestions can determine the methylation status of five CpGs for both genes.
The sequencing after bisulfite treatment was the only option for the CASP8 promoter region because this sequence lacks restriction enzyme sites suitable for BRE and its CpG content is too low for MSP analysis (Banelli et al., 2002) . Expression of the CASP8 gene in primary tumors was determined by RT-PCR analysis and Western blot as previously described (Banelli et al., 2002) .
Statistical analysis
The different extent of methylation among the four genes variably methylated in NTs was evaluated applying the Kruskal-Wallis H-test. This test, which is the nonparametric analog of one-way analysis of variance, allows comparing several independent samples and detects differences in distribution location. The impact of gene methylation on NB patients survival was evaluated using the Cox proportional hazards regression analysis (Kalbfleisch and Prentice, 1980) . We estimated the univariate effect of methylation for each single gene, and then we included in the models major clinical predictors of survival for this disease, that is, the disease stage, the presence of MYCN amplification, the age at diagnosis (infants vs noninfants) and the presence of 1p deletion. The final multivariate models reported in the results included as covariates the stage and the presence of MYCN amplification. Likelihood ratio tests were used to compare candidate models. For those genes whose methylation pattern resulted more associated with survival, that is, RASSF1A and DCR2, and for their combination, we reported the instantaneous relative risk (RR) of the event and corresponding 95% CI. All analyses were performed using Stata statistical software (StataCorp, 2001) and SPSS (SPSS for Windows, 2001 ).
